Drug Trial Radar · NCT01406977
Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)
Last checked: Nov 19, 2026Latest source record: Sep 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jul 2011
Primary completion
Sep 2012
Study completion Sep 2012
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- Collaborators
- Mereo BioPharma; Novartis
- First posted
- Aug 1, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine tolerability, PK/PD and preliminary efficacy of BPS804 in adult patients with HPP treated with multiple escalating doses of BPS804. This study will allow a comparison of several doses of the study drug within the first two weeks after administration and after a longer assessment period for the highest dose level to enable selection of dose ranges to be tested in subsequent studies in the HPP indication.
Conditions
- Hypophosphatasia
Interventions
BPS804Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number (percent) of patients experiencing adverse events or serious adverse eventsTime frame: 141 days following initial investigational product administration
- Change from baseline in primary serological bone biomarkersTime frame: 141 days following initial investigational product administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mereo BioPharma 3 Ltd Investigative Site
Würzburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.